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Effect of parathyroid hormone on energy metabolism of skeletal
muscle. Clinical states with primary or secondary hyperparathyroidism
are associated with muscle dysfunction, suggesting that parathyroid
hormone (PTH) may affect muscle metabolism. The present study
examined the effect of 1-84 PTH and its amino-terminal fragment (1-34
PTH) on energy production, transfer, and utilization by skeletal muscle.
Rats weighing 150 to 200 g were injected intraperitoneally with 1-84 or
1-34 PTH, 200 U/day, for 4 days, and control animals received vehicle
only. The effect of the simultaneous administration of a calcium channel
blocker, verapainil, was examined also. The muscle content of inor-
ganic phosphorus, creatine phosphate, and adenine nucleotides were
significantly (P < 0.01) lower in the PTH-treated rats than in control
animals. The hormone significantly reduced mitochondrial oxygen
consumption without altering ADP:0 ratio, indicating reduced phospho-
rylation. Both 1-84 and 1-34 PTH produced significant (P < 0.01)
reduction in the activities of mitochondrial and myofibrillar CPK, and
mitochondrial MgATPase. 1-84 PTH reduced the activity of myofibrillar
CaATPase as well. There was a significant (P < 0.01) increment in
muscle uptake of 45Ca in the 1-84 PTH-treated rats. Verapamil abol-
ished all the effects of PTH. Our data demonstrate that both 1-84 and
1-34 PTH impair energy production, transfer, and utilization. These
biochemical derangements may, at least in part, underlie the myopathy
observed in conditions associated with excess PTH.
Effets de l'hormone parathyroIdienne sur le métabolisme énergétique
du muscle squelettique. Les situations cliniques associées avec un
hyperparathyroidisme primaire ou secondaire s'accompagnent d'une
dysfonction musculaire qui suggère que l'hormone parathyroidienne
(PTH) peut affecter le métabolisme musculaire. Le present travail a
étudié l'effet du 1-84 PTH et de son fragment aminoterminal (1-34 PTH)
sur La production, le transfert et l'utilisation d'energie par le muscle
squelettique. De Ia 1-84 ou de Ia 1-34 PTH a eté injectee par voie
intraperitoneale a Ia dose de 200 unites par jour pendant 4 jours a des
rats pesant 150 h 200 g, tandis que des animaux contrôles recevaient
uniquement du solvant. Les consequences d'une administration
simultanée de verapamil, un inhibiteur des canaux calciques, ont
egalement été étudiëes. Le contenu musculaire en phosphore
inorganique, créatine phosphate et en adénine-nuciCotides a été trouvé
significativement (p <0.01) plus bas chez les rats ayant recu de La PTH
que chez les animaux contrôles. L'hormone a provoqué une diminution
significative de la consommation des mitochondriales en oxygène sans
altdrer le rapport ADP: 0, indiquant ainsi une diminution de Ia phos-
phorylation. La 1-84 et la 1-34 PTH ont toutes deux produit une
reduction significative (p <0.01) d'activité de Ia CPK mitochondriale et
myofibrillaire, et de Ia MgATPase mitochondriale. La 1-84 PTH a
également réduit l'activité de la CaATPase myofibrillaire. Une augmen-
tation significative (p < 0.01) de la captation de 45Ca par le muscle a été
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observée chez les rats traités par la 1-84 PTH. Le verapamil a aboli tous
les effets de la PTH. Nos résultats démontrent que Ia 1-84 et la 1-34 PTH
empechent toutes deux la production d'énergie, son transfert et son
utilisation. Ces anomalies biochimiques peuvent, au moms en partie,
étre responsables de la myopathie observée dans les situations cliniques
accompagnant un excCs de PTH.
Muscle dysfunction is encountered not infrequently in clini-
cal states with excess parathyroid hormone (PTH). Patients
with chronic uremia who have secondary hyperparathyroidism
[1—4] display evidence of myopathy manifested by muscle
weakness, easy fatiguability, and difficulty in climbing stairs
and rising from a squatting or kneeling position [5, 6]. Also
neuromuscular defects and muscle dysfunction may be encoun-
tered in patients with primary hyperparathyroidism [7—9].
These observations strongly suggest that PTH, at least in part,
underlies the myopathy in these clinical states. The hormone
may exert its effect by affecting protein metabolism and/or
bioenergetics of skeletal muscle.
Indeed, Garber [10] demonstrated that both intact PTH and
its amino-terminal fragment enhance muscle proteolysis and
increase the release of alanine and glutamine. These observa-
tions are consistent with an effect of PTH on muscle protein and
amino acid metabolism.
Data on the effect of PTH on skeletal muscle bioenergetics
are not available. However, PTH has been shown to affect
energy production, transfer, and utilization of another muscular
tissue, the myocardium [1 1]. Theoretically, it is possible that
PTH may exert a similar effect on skeletal muscle as well. The
present study was undertaken to examine this issue.
Methods
This investigation utilized Sprague Dawley rats weighing 150
to 200 g. Preliminary experiments utilizing protocols of 1, 2, and
4 days of PTH administration showed that an obvious effect on
muscle bioenergetics was observed after 4 days of PTH treat-
ment. Therefore, the present study utilized the 4-day protocol.
The rats received intraperitoneal injection of 200 U/day of
1-84 PTH (Sigma Chemical Co., St. Louis, Missouri, USA)
dissolved in normal saline for 4 days, while control animals
received injections of vehicle only. The animals were fed
normal rat chow (ICN Nutritional Biochemical, Cleveland,
Ohio, USA) throughout the study. The various parameters of
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the skeletal muscle bioenergetics were evaluated on the morn-
ing of Day 5. Studies were also carried out utilizing 200 U/day
of 1-34 PTH (Sigma Chemical Co.). In all animals, blood
samples were obtained for the measurements of the concentra-
tion of calcium with Perkin Elmer atomic absorption spectro-
photometer, Model 503 (Perkin Elmer Corp., Norwalk, Con-
necticut, USA) and of inorganic phosphorus with Technicon
autoanalyzer (Technicon Corp., Tarrytown, New York, USA).
Measurement of adenine nucleotides
and creatine phosphate
The rats were anesthetized with an intraperitoneal injection
of 5 mg of pentobarbitallkg body wt, intubated and respirated to
maintain P02 at 85 to 90 mm Hg and PCO2 at 37 to 42 mm Hg.
Muscle biopsy specimens were taken from the medical aspects
of the quadriceps femoris employing freeze-clamping liquid
nitrogen techniques [12]. Inorganic phosphorus, adenine nude-
otides, and creatine phosphate were determined with Bessman
automatic phosphate analyzer [13] as described previously from
our laboratory [14]. By means of relative retention times, the
peaks obtained in a chromatogram of the biopsy specimen were
compared with those obtained by using synthetic standards. All
peaks of interest were identified both by internal standards and
chromatography with a known amount of authentic com-
pounds. Recovery for individual metabolites was evaluated
using measurements of known standards with and without the
column. Creatine was measured by an enzymatic method [15],
and protein was determined employing a modification of the
method described by Lowry et al [16].
Evaluation of mitochondrial energy
production and transport
Mitochondrial energy production was examined using
mitochondria isolated by the method described by Yang, Gei-
ger, and Bessman [17]. The rats were sacrificed by decapitation,
and skeletal muscle from the hind limb was removed and
washed of blood. The muscle specimens were placed in an
ice-cold homogenization medium containing 0.3 M mannitol, 0.1
mM EDTA, and 10 m Tris buffer at pH 7.2. The tissue was
then cut into small pieces, run through a Harvard tissue press,
and treated for 30 mm with trypsin. At the end of 30 mm, a
trypsin inhibitor was used to stop the reaction. The fine tissue
was then homogenized with a Dounce-type homogenizer. After
final homogenization, the homogenate was centrifuged for 10
mm, at 400g in an International refrigerated centrifuge. The
pellet was discarded and the supernatant centrifuged at 8,000g
for 10 mm, for final isolation of mitochondria. The mitochon-
drial pellet was washed several times, and then suspended in a
medium containing homogenization medium, 0.5% (wt/vol)
dialyzed albumin, and 10 ifiM Tris phosphate buffer, pH 7.2.
The protein concentration of the mitochondrial pellet was
determined by a modification of the Lowry method [16].
The substrate oxidation rate and ADP/0 ratio were deter-
mined polarographically by means of a Clark oxygen electrode
(Gilson Medical Electronics, Middleton, Wisconsin, USA) fit-
ted to a Plexiglas chamber of 2.0 ml capacity as described
originally by Chance and Williams [181. The complete system
contained 1 mg mitochondrial protein added to 2 ml of incuba-
tion medium containing (in mM): 50 KC1, 10 Tris HC1 buffer (pH
7.4), 10 to 20 potassium phosphate buffer (pH 7.4), 8 MgC12, 65
sucrose, 0.2 cytochrome c, 1 NAD, 0.5 EDTA, and 0.05%
bovine serum albumin. The substrate used in our incubate was
3.5 mM alpha-ketoglutarate. The principle of this methodology
is based on the observation that when tightly coupled
mitochondria are suspended in an isotonic buffer, a slow rate of
oxygen uptake is measured in the presence of substrate and
absence of ADP. The addition of ADP will cause an immediate
increase in oxygen uptake, dependent on the concentration of
ADP added to the reaction. The rate of oxygen uptake is
directly related to the amount of ADP phosphorylated to ATP.
Maximal oxygen consumption was achieved by the addition of
ADP in excess (17 mM). Respiratory control ratio is defined as
the rate of state 3 respiration (mitochondria + ADP + sub-
strate) divided by the rate of state 4 respiration (mitochondria +
substrate + ATP) [18]. To evaluate further the process of
coupling between mitochondrial electron transport and ATP
production, the activity of Mg ATPase was determined utilizing
the method of Mitnacht, Sherman, and Farber [19]. The activity
of mitochondrial magnesium-stimulated ATPase was deter-
mined by measuring the liberation of inorganic phosphate from
6 m ATP in a 2 ml reaction medium containing intact
mitochondria (2 to 3 mg protein), 74 mrvi KC1, 50 mM sucrose,
50 mM Tris HC1 (pH 7.4), and 1 m EDTA. In all measure-
ments, magnesium was present at the concentration of 4 m to
assess specificity of the reaction.
Since energy transport from the mitochondria occurs via the
creatine phosphate shuttle [20, 21] and is regulated at least in
part by the mitochondrial creatine kinase isoenzyme [21, 22],
the effect of PTH on the activity of this enzyme was measured.
Assay for mitochondrial creatine kinase used the modification
of a method described by Oscai and Holloszy [23]. The activity
of creatine kinase was measured utilizing a system coupled with
pyruvate kinase and lactate dehydrogenase. The assay mixture
contained, in the final volume of 1 ml, 50 smoles Tris HC1, pH
9.0, 5 tmoles ATP, 30 moles creatine, 2.4 /Lmoles phospho-
enolpyruvate, 0.15 smoles NADH, and 50 mg lactate dehydrog-
enase. The reaction was started by adding creatine, and the
oxidation of NADH was followed spectrophotometrically.
Evaluation of energy utilization
Since energy utilization by the contractile myofibrils is me-
diated via the myofibrillar creatine kinase isoenzyme and Ca
ATPase, the effects of PTH on the activity of these enzymes
were examined. Skeletal muscle myofibrils were isolated and
purified according to the method of Solaro, Pang, and Briggs
[24]. The muscular tissue was trimmed of fat and homogenized
for 1 nun in 4 vol of a 0.3M sucrose solution containing 10 mM
imidazole (pH 7.0). The homogenate was centrifuged at 17,300g
for 20 mm, and the pellet was suspended in a standard buffer
solution containing 60 mri KCI, 30 mivi imidazole (pH 7.0), and
mM MgCl2. This process of homogenization, centrifugation,
and resuspension was repeated 4 times. The myofibrils were
further purified by several washings with standard buffer con-
taining 1% Triton. The purified myofibrils were resuspended in
standard buffer to a protein concentration of 8 to 10 mg/dl. The
activity of creatine kinase was determined and expressed per
milligram protein. Myofibrillar Ca ATPase was measured by a
method described previously [25].
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Measurements of 45Ca uptake
The uptake of 45Ca by the skeletal muscle was determined by
a modification of the method of Fleckenstein et al [261. After 4
days of 1-84 PTH or vehicle administration, the animals re-
ceived 20 Ci of 45Ca per kg body wt intraperitoneally at 6A.M.,
of Day 5 of the study. Six hr later, the animals were sacrificed
by decapitation, blood was collected, and a skeletal muscle
sample was obtained and its wet weight determined. The
muscle tissue was dissolved in soluene x-100 (Packard Instru-
ment Corp., Downers Grove, Illinois, USA); 1 ml of soluene
was used per 1 mg wet wt tissue. 45Ca in blood and muscle
samples was determined with Beckman Liquid Scintillation
Counter Model L 5700 (Beckman Instruments, Irvine, Califor-
nia, USA). The myocardial uptake of 45Ca was expressed as
percentage uptake in 1 g wet tissue relative to the counts in 100
ml of blood.
Evaluation of the effect of verapamil on the action
of 1-84 PTH
The effects of verapamil (Isoptene, Knoll AG,
Ludwigschagen, Germany) given intraperitoneally in a dose of
2 mg/kg body wt/day for 4 days to normal rats or to 1-84
PTH-treated animals on all parameters of myocardial
bioenergetics, 45Ca uptake, and total calcium content were
examined.
Results
The dose of 200 U of PTH used in the present study did not
cause a significant rise in the blood levels of calcium, and the
values were 9.5 0.12 mg/dl in the control rats and 9.9 0.22
mg/dl in the PTH-treated animals. However, there was a
significant (P < 0.01) decrease in the blood concentration of
inorganic phosphorus, with the values being 7.8 0.15 mg/dl in
the control animals and 6.1 0.14 mg/dl in the PTH-treated
rats.
The effects of 1-84 PTH on skeletal muscle content of
inorganic phosphorus (Pi), creatine phosphate (CP), and aden-
osine triphosphate (ATP) are given in Figure 1. The adminis-
tration of 1-84 PTH produced a significant (P < 0.01) decrease
in the content of Pi (control vs. PTH, 32.0 + 3.0 vs. 14.3 2.5
(SE) moles/g protein), Cp (86.8 8.9 vs. 46.5 4.6 tmoles/g
protein), and ATP (37.6 2.2 vs. 20.1 0.9 moles/g protein).
The content of ADP (4.9 0.6 vs. 2.6 0.3 moles/g protein,
P < 0.01) and AMP (2.8 0.2 vs. 1.9 0.3 smoles/g protein,
P < 0.05) were also reduced in PTH-treated rats. There was no
change in ATP/ADP ratio during PTH administration. The
changes in CP content occurred despite no change in muscle
content of total creatine (control vs. PTH, 123 12.8 vs. 133
9.7 jsmoles/g wet wt).
The respiratory control rates of muscle mitochondria in
control animals (12.8 0.7), in 1-84 PTH-treated animals (9.4
0.6), in 1-34 PTH-treated animals (10.4 0.7), in those treated
with verapamil alone (13.3 0.9), and in those receiving
verapamil and PTH (10.0 0.9) were within the range of intact
coupled mitochondria. The effects of PTH, verapamil, and PTH
on mitochondrial oxygen consumption are given in Figure 2.
Oxygen consumption was significantly (P < 0.01) decreased by
0
Fig. 2. Effects of 1-84 PTH, 1-34 PTH, verapamil, and verapamil and
1-84 PTH on oxygen consumption of skeletal muscle mitochondria.
Each bar represents the mean value and the brackets 1 5E. The
decrements produced by 1-84 PTH and 1-34 PTH are significant with P
< 0.01. Symbols are: E, control; •, 1-84 PTH; A, 1-34 PTH; ll,
verapamil; , verapamil + 1-84 PTH.
the administration of both 1-84 PTH (control vs. PTH, 216 7.6
vs. 174 6.1 nmoles 02/mg protein/mm) and 1-34 PTH (216
7.6 vs. 155 8.2 nmoles 02/mg protein/mm). The simultaneous
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Fig. 1. Effect of 1-84 FTH on skeletal muscle contents of creatine
phosphate, inorganic phosphorus, and ATP. Each bar represents the
mean value and the brackets 1 SE. The decrement produced by PTH are
all significant with P < 0.01. Symbols are: EJ, control; , PTH-treated.
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Table 1. Effects of 1-84 PTH, 1-34 PTH, verapamil, and verapamil and 1-84 PTH on the activities of mitochondrial creatine phosphokinase and
Mg ATPase and on myofibrillar creatine phosphokinase and Ca ATPase
Mitochondria Myofibrils
Creatine phosphokinase Mg ATPase
lU/mg protein mmoles Pi/mg protein/mm
Creatine phosphokinase Ca ATPase
lU/mg protein mmoles Pi/mg protein/mm
Control 2.71 0.16
1-84 PTH 1.94 0.18*
1-34 PTH 1.23 0.07*
Verapamil 2.84 0.09
Verapamil and 1-84 PTH 2.90 0.20
394 13
210 12*
217 9*
406 17
428 7
1.39 0.04
0.82 0.07*
1.21 0.04*
1.25 0.06
1.45 0.07
362 17.8
234 8.0*
322 12.1
372 19.4
362 21.5
Data are presented as mean SE.
* Denotes significant difference from control with P < 0.01.
administration of verapamil with 1-84 PTH abolished the effect
of PTH on mitochondrial oxygen consumption (control, 216
7.6; PTH, 174 6.1; verapamil and PTH, 201 8.0 nmoles
02/mg protein/mm). The ADP/O ratio in control animals (2.72
0.03) was not different than those in rats treated with 1-84 PTH
(2.80 0.03), 1-34 PTH (2.75 0.03), verapamil (2.70 0.04),
or verapamil and 1-84 PTH (2.68 0.04).
The effects of 1-84 PTH, 1-34 PTH, verapamil, and verapamil
and 1-84 PTH on the activity of the enzymes associated with
energy production, transfer, and utilization are given in Table 1.
1-84 PTH produced significant (P < 0.01) decrements in the
activity of mitochondrial creatine phosphokinase (CPK) and Mg
ATPase and of myofibrillar CPK and Ca ATPase. A similar
effect was also noticed with 1-34 PTH, except for the activity of
myofibrillar Ca ATPase. The activity of the latter enzyme was
reduced, but the change did not reach statistical significance.
Verapamil abolished these effects of the hormone.
The effects of 1-84 PTH, verapamil, and verapamil and PTH
on 45Ca uptake by the muscle are depicted in Figure 3. The
administration of 1-84 PTH produced a significant (P < 0.01)
increase in the 45Ca uptake (control vs. PTH, 52 2.7% vs. 68
2.2%). The simultaneous administration of verapamil with
1-84 PTH abolished the enhanced uptake of calcium.
Discussion
The results of the present study demonstrate that the skeletal
muscle, as the myocardium, is a target organ for PTH and that
the hormone affects various steps of muscle energy metabolism.
There was a decrease in energy production, as evidenced by
reduced ATP content, mitochondrial oxygen consumption, and
activity of mitochondrial Mg ATPase. In addition, PTH admin-
istration produced a decrease in CP content and in the activity
of mitochondrial CPK, indicating impaired energy transport.
Finally, energy utilization was also affected, as demonstrated
by decreased activity of both myofibrillar CPK and Ca ATPase.
These effects appear to be specific to the hormone since they
were induced by both purified 1-84 PTH and by the synthetic
pure 1-34 PTH.
The decrease in ATP content could be due to increased
breakdown or reduced synthesis. An increase in ATP consump-
tion should be associated with a rise in Pi, but the latter was
reduced following PTH treatment, making increased ATP
breakdown an unlikely possibility. Two findings in our study
are consistent with the notion that decreased ATP synthesis is
a more plausible mechanism for the reduced ATP content
following PTH administration. First, the fall in the concentra-
tion of Pi reduced the availability of substrate for ATP synthe-
sis; second, the inhibition of mitochondrial oxygen consump-
tion without a fall in the ADP:0 ratio indicates reduced mito-
chondrial capacity to generate ATP.
It should be mentioned that our measurements of myocardial
high energy compounds and Pi represent total values and may
not reflect changes in free levels of these compounds, which are
the determinants of the true energy state of the tissue. Free
concentrations of Pi and ADP could be determined accurately
by the use of 31P nuclear magnetic resonance, a method which
has not been utilized in our studies. The interpretation of our
results is made with this limitation in mind.
Our data do not support the view that the reduction in CP is
due to membrane leakage, since total creatine was unchanged.
Since CP content depends on the availability of creatine, ATP,
and the activity of mitochondrial creatine phosphokinase, and
since total creatine did not fall, the reduced content of ATP and
the impaired activity of creatine phosphokinase are the most
likely changes responsible for the decrease in CP content.
It has been shown that calcium overload in the myocardium
causes a reduction in ATP content [27] and impairment in
mitochondrial and myofibrillar steps of cellular bioenergetics
80
60
0
Fig. 3. Effect of 1-84 PTH, verapamil, and verapamil and 1-84 PTH on
45Ca uptake by skeletal muscle. Each bar represents the mean value and
the brackets 1 SE. The increase in 45Ca uptake induced by 1-84 PTH is
significant with P < 0.01. Symbols same as Fig. 2.
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[11]. It is possible that the effects of PTH on muscle energy
metabolism may also be related to enhanced entry of calcium
into the muscle by the hormone. Two observations in our study
support this notion. First, PTH administration produced a
significant increase in 45Ca uptake by the muscle. Second, the
simultaneous administration of a calcium channel blocker,
verapamil, abolished the PTH-mediated enhanced 45Ca uptake
and the effects of PTH on mitochondrial oxygen consumption
and on the activity of the enzymes regulating energy produc-
tion, transfer, and utilization.
Palmieri et al [28] reported that PTH plays a role in muscle
dystrophy in the hamster, and parathyroidectomy was followed
by improvement of the muscular lesion. Their data pemitted
them to conclude that the accentuation of the dystrophic
process is most likely related to PTH-induced enhanced cal-
cium flux into the muscle. Thus, these observations are con-
sistent with our suggestion that increased calcium entry into
muscle exerts an adverse effect on its metabolism.
The decrease in Pi content of the muscle during PTH admin-
istration may also contribute to the mechanism through which
PTH exerts its effects on muscle bioenergetics. A decrease in
muscle Pi occurs in phosphate depletion which is associated
with impaired mitochondrial oxygen consumption and reduced
activity of mitochondrial and myofibrillar CPK [29]. However,
ATP and CP contents are not reduced in phosphate depletion
[291, in contrast to the significant fall in ATP and CP during
PTH administration. Thus, it is reasonable to suggest that the
decrease in muscle Pi could contribute to some of the effects of
PTH on muscle energy metabolism.
The mechanisms through which PTH reduces muscle Pi are
not evident, but a similar observation was reported by Meyer
and Meyer [30] who found a decrease in total phosphorus
content in liver and skeletal muscle during PTH administration.
One may speculate that the excess calcium entering the cell
may precipitate as calcium phosphate compound reducing the
concentration of inorganic phosphorus. Indeed, Lehninger,
Rossi, and Greenawalt [31] have shown that calcium phosphate
precipitates in the mitochondria of liver cells during calcium
loading. This process requires energy and organic phosphorus.
Electron-opaque deposits of insoluble calcium salts have been
noted in kidney mitochondria exposed to excess PTH [32].
An alternative explanation for our results could be related to
the effect of PTH on muscle proteolysis described by Garber
[10]. With such an interpretation, one would suggest that PTH
reduces the energy production apparatus, but that which re-
mained has the same functional capacity. Such a situation
would result in reduced high energy compounds. This explana-
tion finds support in our observation that CP/Pi ratio, consid-
ered by some as an index of energy capability, is not worsened
by PTH administration. If these arguments provide the entire
explanation for our results, the demonstration that the blocking
of the PTH-induced calcium entry by verapamil corrected the
changes in energy production and shuttle would suggest that the
enhanced calcium entry into muscle plays a major role in
PTH-induced proteolysis. Unfortunately, Garber's data [10] do
not confirm nor refute such a potential mechanism of PTH on
muscle protein metabolism.
The results of our study, those of Palmieri et a! [28], and
those of Garber [10] indicate that PTH affects muscle structure,
its calcium content, its bioenergetic and its protein and amino
acid metabolism. The latter abnormality could underlie some of
the other derangements. These multiple effects of PTH would
affect muscle and may underlie the myopathy seen in patients
with primary and secondary hyperparathyroidism.
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